Supply of Plasmids and Synthetic DNA for Viral Vector Manufacture

Descriptions

As part of a preliminary market engagement exercise, NHS Blood & Transplant (NHSBT) are seeking to engage with suppliers of nucleic acids including plasmid DNA; synthetically produced DNA and/or enzymatically produced DNA. The intended use of the nucleic acids by NHSBT includes: a) the GMP grade production of gene therapy vectors such as lentiviral, adeno-associated viral vectors and novel gene therapy vectors, for clinical trials and commercial production where applicable; b) gene therapy vectors suitable for pre-clinical studies, such as toxicology and biodistribution studies and gene therapy vectors suitable for R&D purposes.